Acumen Pharmaceuticals Inc. (ABOS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.21 (-90.82% 1D, market cap $165.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ABOS ranks #582 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ABOS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, ABOS leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).
Per ABOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576885), Acumen Pharmaceuticals Inc. generated $0 in revenue, -$121.3M in net income, and -$115.5M in free cash flow against $122.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20.3 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ABOS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.41) and Max Pain ($0.22) forces dealer call-delta covering toward $3.78.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Acumen Pharmaceuticals Inc. (ABOS) dropped -90.82% to $0.21, trading at 2% of its 52-week range ($0.21 – $3.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
CNN report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.
Acumen Pharmaceuticals' lead Alzheimer's drug sabirnetug failed to show clinical efficacy in the ALTITUDE-AD trial. See why ABOS stock is downgraded to a sell.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ABOS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ABOS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Acumen Pharmaceuticals Inc. (ABOS) ranks #582 by composite RQD confidence (38/100, grade D-) and #600 by equity capitalization ($165.6M). Within this direct 5-issuer industry benchmark cohort, ABOS leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. IPHA currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with ABOS at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABOS
ACTIVE
Acumen Pharmaceuticals Inc. | D- | 38/100 | — | — | -35.0% | -90.82% | $165.6M | Benchmark Subject |
| IPHA Innate Pharma S.A. ADS | D+ | 52/100 | — | — | — | -2.67% | $167.6M | /ipha-vs-abos → |
| IVVD Invivyd Inc. | E | 30/100 | — | — | -35.0% | -3.37% | $177.4M | /ivvd-vs-abos → |
| STRO Sutro Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -0.44% | $151.6M | /stro-vs-abos → |
| TARA Protara Therapeutics Inc. | D- | 43/100 | — | — | -34.7% | -1.59% | $148.9M | /tara-vs-abos → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Acumen Pharmaceuticals Inc. (ABOS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$121.3M, operating cash flow of -$115.5M, and free cash flow of -$115.5M (-34.0% YoY). On the balance sheet, ABOS closed FY2025 with $122.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$121.3M | -$115.5M | -$115.5M | $122.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$102.3M | -$86.2M | -$86.2M | $239.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$52.4M | -$43.1M | -$43.1M | — | — |
As of 2026-11-02, Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.21 (-90.82% 1D, market cap $165.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ABOS ranks #582 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ABOS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $167.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, ABOS leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).
Per ABOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001576885), Acumen Pharmaceuticals Inc. generated $0 in revenue, -$121.3M in net income, and -$115.5M in free cash flow against $122.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ABOS last traded at $0.21 (-90.82% on volume of 68,105,161 shares), positioning the stock -91.29% below its 50-day simple moving average ($2.41) and -91.60% below its 200-day simple moving average ($2.50). Across its 52-week range of $0.21 to $3.60, ABOS sits at the 0.0% percentile with a 14-day RSI of 20.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.24).
Why ABOS Stock dropped -90.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ABOS carries an RQD Score of 38 out of 100, a letter grade of D-, and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows: Fundamental Cash Engine 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 7/20 (institutional accumulation and options positioning), Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
Taken together, the lowest-scoring pillars point to weak cash generation and weak signals of insider conviction. The fundamental pillar reflects a negative ROIC and a 0% FCF yield, meaning the company is not currently converting capital into free cash flow, a condition that typically places pressure on valuation and funding needs. The insider pillar's low score indicates limited evidence of insider conviction in the source flow. Institutional and options signals score modestly higher but do not offset the fundamental weakness. The forensic pillar sits at the midpoint of its range: a Piotroski F-Score of 2 out of 9 is weak, while an Altman Z-Score of 2.5 is not in itself a distress signal in this dataset, and Debt/Equity of 0.5 is moderate. Macro fit is neutral-to-weak with a Beta of 1.0, meaning the stock is assessed as moving in line with the broader market.
For a prospective investor evaluating the stock today, the principal upside driver would be a change in cash generation; the source data shows none yet. The principal valuation tradeoff is that the price of 0.21 and market capitalization of $165.6M reflect a stock that has fallen sharply, per the market data (-90.83%). The rating itself is a snapshot and is not a recommendation.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-123.8M | $-121.3M | N/A | $-115.5M | $54.0M | N/A |
| FY 2024 | $0.0M | $-114.0M | $-102.3M | N/A | $-86.2M | $35.6M | N/A |
| FY 2023 | $0.0M | $-61.1M | $-52.4M | N/A | $-43.1M | N/A | N/A |
Per the SEC financials, the company reported no revenue and widening operating losses across the three periods, with net losses of $-52.4M, $-102.3M, and $-121.3M. Operating margin, gross margin, and net margin are each reported as 0% in the market data, and ROIC is -35%. Free cash flow was negative in every period. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, with Debt/Equity of 0.5. Reported cash rose from $35.6M to $54.0M, while debt is listed as N/A in the source data.
Recent news items from the source data are headlined as market wire reports, all tagged "YELLOW" for impact. One item, a Seeking Alpha report, carries the headline "Acumen Pharmaceuticals Stock: ALTITUDE-AD Failure Destroys The Investment Thesis (ABOS)," which is the most significant catalyst-related headline in the feed; the source data does not provide further detail on the trial. The remaining items are generic quote, price, and options-chain pages with no additional content. The Butterfly supply-chain graph reports no supply-chain linkages and no proprietary signals.
Risk watch items from the data include the reported negative free cash flow, the -90.83% price change, and the single failure-related headline. Not available in source data for any trial outcome details, guidance, or upcoming catalysts.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream dependencies, downstream customers, or sector correlation mapping.
Real-time company headlines, analyst actions, and sector developments for Acumen Pharmaceuticals Inc. (ABOS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
CNN report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Acumen Pharmaceuticals Inc. (ABOS) market action, institutional positioning, and fundamental catalysts.
Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
Welcome to the ABOS (Acumen Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ABOS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Acumen Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ABOS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.21 (52-wk range $0.21 - $3.60), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).